Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Pharmacia Clears FTC: Viagra Patent Strategy, HRT Safety Are Factors

Executive Summary

Pfizer's patent defense strategy for Viagra is one reason the Federal Trade Commission is requiring the divestiture of Phase II erectile dysfunction disorder agents as a condition of the Pfizer/Pharmacia merger

You may also be interested in...



Pfizer R&D Reshuffling Deals Out Pharmacia’s Investment In Sugen

Pfizer will cease investment in the biotech company Sugen as part of a reorganization of Pfizer/Pharmacia's combined R&D facilities

HRT Class Labeling Should Not Cover Topical Estrogens, Pharmacia Says

Topical hormone therapy drugs should be exempt from FDA's proposed estrogen class labeling incorporating safety information from the Women's Health Initiative study, Pharmacia maintained in comments submitted to the agency

Pfizer R&D Reshuffling Deals Out Pharmacia’s Investment In Sugen

Pfizer will cease investment in the biotech company Sugen as part of a reorganization of Pfizer/Pharmacia's combined R&D facilities

Related Content

UsernamePublicRestriction

Register

OM017175

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel